Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Receivables: 2017-2019

Historic Receivables for Protagonist Therapeutics (PTGX) over the last 3 years, with Dec 2019 value amounting to $6.3 million.

  • Protagonist Therapeutics' Receivables rose 48.84% to $4.1 million in Q1 2021 from the same period last year, while for Mar 2021 it was $16.2 million, marking a year-over-year increase of 1.42%. This contributed to the annual value of $6.3 million for FY2019, which is 119.17% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Receivables of $6.3 million as of FY2019, which was up 119.17% from $2.9 million recorded in FY2018.
  • Protagonist Therapeutics' Receivables' 5-year high stood at $6.3 million during FY2019, with a 5-year trough of $1.9 million in FY2017.
  • Over the past 3 years, Protagonist Therapeutics' median Receivables value was $2.9 million (recorded in 2018), while the average stood at $3.7 million.
  • Data for Protagonist Therapeutics' Receivables shows a peak YoY skyrocketed of 119.17% (in 2019) over the last 5 years.
  • Yearly analysis of 3 years shows Protagonist Therapeutics' Receivables stood at $1.9 million in 2017, then spiked by 52.29% to $2.9 million in 2018, then spiked by 119.17% to $6.3 million in 2019.